Company intelligence / Profile preview

eGenesis

Cambridge, Massachusetts, United Statesegenesisbio.com ↗

Ownership: Private
Employees: ~150
Development stage: Other

Overview

eGenesis achieved the world’s first successful porcine kidney transplant into a living patient in March 2024. The lead candidate kidney carries three classes of genetic edits to address immunological rejection and viral safety. Durable preclinical success has been demonstrated across multiple organ types. The company’s approach offers a potential solution to the global shortage of transplantable organs by providing genetically engineered animal organs compatible with humans.

Therapeutic areas: GastroenterologyCardiovascularNephrology
Modalities: Multiplex gene editing (CRISPR-based)genome engineeringxenotransplantation of organs and cells
Industry: Biotech

Drug pipeline

3 assets

EGEN-5784

2 more assets in the full pipeline.

Partnerships

Massachusetts General Hospital (for clinical trial/execution)Lux Capital

Beyond the preview

Go deeper on eGenesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eGenesis.